VTRS — Viatris Inc

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1792044 ·
Last close
$20.45
Market Cap
$23.45B
52W High
$21.20
52W Low
$9.80
ADV30
9,643,446
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 3,749,500,000 1,438,000,000 255,500,000 -325,300,000 34,682,600,000 1,789,200,000 20,997,100,000
Jun 2026 3,756,800,000 1,456,500,000 73,700,000 -118,800,000 35,044,600,000 886,500,000 20,784,200,000
Mar 2026 3,517,000,000 1,157,200,000 -20,200,000 176,400,000 36,834,600,000 1,804,200,000 22,176,900,000
Dec 2025 3,703,600,000 1,147,900,000 -157,500,000 -340,100,000 37,193,100,000 1,322,400,000 22,481,800,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$2,485,300,000
Investing CF
$306,900,000
Financing CF
$-1,972,600,000
CapEx
$-507,500,000
Dividends Paid
$-555,100,000
Buybacks
$-385,100,000
EPS Diluted TTM
$-0.53
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-656,000,000
Inventory
$3,829,200,000
Receivables
$3,420,100,000
ST Investments
$217,100,000
EBIT TTM
$-53,600,000
Pretax Income TTM
$-526,400,000
Interest Exp TTM
$472,800,000
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$14,726,899,712
EBITDA
$4,376,399,872
Free Cash Flow
$3,158,449,920
Enterprise Value
$34,398,912,512
Total Cash
$2,006,300,032
Total Debt
$13,579,299,840
Shares Out
1,146,454,729
Trailing EPS
$-0.53
Book Value
$11.94
ROE
-4.2%
ROA
2.9%
Div Yield
2.41%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 14,299,900,000 253,500,000 -3,514,900,000 37,193,100,000 22,481,800,000 14,711,300,000 2,315,900,000
Dec 2024 14,739,300,000 710,300,000 -634,200,000 41,500,900,000 22,865,400,000 18,635,500,000 2,302,900,000
Dec 2023 15,426,900,000 1,563,400,000 54,700,000 47,685,500,000 27,218,100,000 20,467,400,000 2,900,000,000
Dec 2022 16,262,700,000 1,655,700,000 2,078,600,000 50,022,200,000 28,949,900,000 21,072,300,000 2,999,000,000

TTM Snapshot

Revenues TTM
$14,737,300,000
NetIncome TTM
$-410,700,000
OpCashFlow TTM
—
Assets (Latest)
$35,044,600,000
Forward EPS
$2.75

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $18.00 · spot: $20.28 · call volume: 205 · put volume: 468
Expected Move to 2027-01-15: ±$2.16 (10.65%) — implied range $18.12 – $22.44 · ATM straddle on $20.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
UTHR UNITED THERAPEUTICS Corp $24.88B $584.10 —
ALNY ALNYLAM PHARMACEUTICALS, INC. $20.96B $156.50 —
INSM INSMED Inc $26.73B $121.86 —
ROIV Roivant Sciences Ltd. $28.05B $38.71 —
RPRX Royalty Pharma plc $30.58B $68.68 —

News headlines (Yahoo Finance, 1h cache)

Viatris Completes Acquisition of Pacira BioSciences
2026-11-17 13:50 · Yahoo
Are Investors Undervaluing Viatris (VTRS) Right Now?
2026-11-17 13:40 · Yahoo
CADILLAC FORMULA 1® TEAM WELCOMES VIATRIS AS OFFICIAL GLOBAL PHARMACEUTICAL PARTNER
2026-11-16 14:00 · Yahoo
Viatris to Participate in Upcoming Investor Conferences
2026-11-11 11:59 · Yahoo
VTRS or DHR: Which Is the Better Value Stock Right Now?
2026-11-10 19:38 · Yahoo
Viatris Inc. (VTRS) Hit a 52 Week High, Can the Run Continue?
2026-11-10 13:15 · Yahoo
VTRS Q3 2026 deep dive: new product launches and Pacira acquisition shape outlook
2026-11-10 08:45 · Yahoo
Viatris (VTRS) Stock May Be Below Fair Value Despite A $1.65B Deal
2026-11-08 01:15 · Yahoo
Viatris (VTRS) Earnings Beat And Higher Outlook Put Fair Value Back In Focus
2026-11-07 09:17 · Yahoo
Are Wall Street Analysts Predicting Viatris Stock Will Climb or Sink?
2026-11-06 12:03 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.